πŸ‡ΊπŸ‡Έ

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

Credit: Business Wire- Published 5 days ago
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced that all the conditions are in place for the upcoming start of the Phase II trial testing the antibiotic candidate DNV3837 for the treatment of Clostridioides difficile infections. DNV3837 is a first-in-class antibiotic candida
Advertisement

You are here

More: Beauty

You might like